Recombinant MS4A1 (Obinutuzumab Biosimilar) antibody

Catalog No. ABIN7795118

This Mouse Monoclonal antibody specifically detects MS4A1 (Obinutuzumab Biosimilar) in FACS and in vivo. It exhibits reactivity toward Human.

Quick Overview for Recombinant MS4A1 (Obinutuzumab Biosimilar) antibody (ABIN7795118)

Target: MS4A1 (Obinutuzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This MS4A1 (Obinutuzumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-MS4A1 (Obinutuzumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Obinutuzumab Biosimilar, CD20 Monoclonal Antibody

Characteristics: Obinutuzumab Biosimilar uses the same protein sequences as the therapeutic antibody obinutuzumab. Obinutuzumab is an antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil. In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human CD20

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for MS4A1 (Obinutuzumab Biosimilar)

Target: MS4A1 (Obinutuzumab Biosimilar)

Alternative Name: Obinutuzumab Biosimilar

Target Type: Biosimilar